Resolution Therapeutics Announces £63.5 Million Series B …

Oct 3, 2024 · EDINBURGH, Scotland and LONDON, Oct. 3, 2024 /PRNewswire/ -- Resolution Therapeutics Limited ("Resolution"), a clinical-stage biopharmaceutical company focused on …

CouponFollow Extension

£63
OFF

Resolution Therapeutics Announces £63.5 Million Series B …

6 days from now

Oct 3, 2024 · EDINBURGH, Scotland and LONDON, Oct. 3, 2024 /PRNewswire/ -- Resolution Therapeutics Limited ("Resolution"), a clinical-stage biopharmaceutical company focused on …

prnewswire.com

£63
OFF

Resolution Therapeutics Announces £63.5 Million Series B …

6 days from now

Mar 10, 2024 · Edinburgh and London, UK, 3 October 2024 – Resolution Therapeutics Limited (“Resolution”), a clinical-stage biopharmaceutical company focused on unlocking the …

synconaltd.com

£63
OFF

Edinburgh’s Resolution Therapeutics Raises £63m

6 days from now

Oct 3, 2024 · Edinburgh-based Resolution Therapeutics Limited announced it has raised £63.5 million in Series B financing round led by investment firm Syncona Ltd. Resolution is a clinical …

scottishfinancialreview.com

£63
OFF

Resolution Therapeutics Announces £63.5 Million Series B …

6 days from now

Oct 3, 2024 · Resolution raises £63.5M series B financing from Syncona and appoints Paul Sekhri as Chair of the Board of Directors. ... Edinburgh and London, UK, 3 October 2024 – Resolution …

resolution-tx.com

£63
OFF

Resolution Therapeutics Raises £63.5M In Series B Financing

6 days from now

Oct 3, 2024 · Resolution Therapeutics, an Edinburgh, Scotland, and London, UK-based clinical-stage biopharmaceutical company, raised £63.5M in Series B funding.. The round was led by …

finsmes.com

£64
OFF

Resolution’s £64M Series B To Advance Macrophage Cell Therapy

6 days from now

Oct 3, 2024 · A preview of the next edition of BioWorld, Oct. 3, 2024. Resolution Therapeutics Ltd. is preparing for a phase I/II trial of its autologous engineered macrophage cell therapy, RTX …

bioworld.com

£63
OFF

Resolution Therapeutics Raises £63.5 Million In Series B Financing …

6 days from now

Oct 3, 2024 · The Series B financing brings the total amount raised by Resolution to £101.4 million. Following the drawdown of the full Series B financing, Syncona's ownership stake in …

pharmiweb.com

$83
OFF

Resolution Scores $83m To Develop Macrophage Cell Therapies

6 days from now

Oct 3, 2024 · Resolution Therapeutics has raised £63.5m ($83.3m) in a Series B financing round to develop its macrophage cell therapies. The UK-based company plans to use the money to …

pharmaceutical-technology.com

$83
OFF

Resolution Therapeutics Secures $83M To Advance Liver Therapy

6 days from now

Oct 3, 2024 · Resolution Therapeutics was co-founded by Syncona, a UK-based investment trust focused on helping to found, fund and progress healthcare companies, in 2020 after a two …

biopharma-reporter.com

FAQs about Resolution Therapeutics Announces £63.5 Million Series B … Coupon?

What is resolution Therapeutics?

About Resolution Therapeutics Resolution Therapeutics is a clinical-stage biopharmaceutical company focused on unlocking the regenerative potential of macrophage therapy for the treatment of inflammatory and fibrotic diseases. ...

Is resolution a regenerative biopharmaceutical company?

EDINBURGH, Scotland and LONDON, Oct. 3, 2024 /PRNewswire/ -- Resolution Therapeutics Limited ("Resolution"), a clinical-stage biopharmaceutical company focused on unlocking the regenerative potential of macrophage therapy for the treatment of inflammatory and fibrotic diseases, today announces it has raised £63.5 million in Series B financing. ...

How much did resolution raise in Series B financing?

Resolution announced this week that it had raised £63.5 million (US$ 83 million) in Series B financing. The round adds to an earlier £26.6 million (US$ 35 million) Series A financing in 2020. ...

Does resolution Therapeutics secure Spanish liver disease trial approval?

"Resolution Therapeutics secures Spanish liver disease trial approval" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. ...

What can resolution do for esld patients?

Resolution has also developed a platform to engineer and cryopreserve autologous macrophages with a pro-regenerative phenotype for the treatment of patients with ESLD. The data showcase an improved differentiation protocol and a more automated process to maximise manufacturing yields without compromising the phenotype. ...